Упрощенная HTML-версия
143
178. Eikelboom J.W. Aspirin resistance and its implications in clinical
practice / J.W. Eikelboom, M. Feldman, S.R. Mehta et al. // Med. Gen. Med. –
2005. – Vol. 7 (3). – Р. 76.
179. Eikelboom J.W. Aspirin-resistant thromboxane biosynthesis and the
risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk
for cardiovascular events / J.W. Eikelboom, J. Hirsh, J.I. Weitz et al. // Circulation.
– 2002. – Vol. 105. – Р. 1650–1655.
180. Eikelboom J.W. Enhanced antiplatelet effect of clopidogrel in patients
whose platelets are least inhibited by aspirin: a randomized crossover trial / J.W.
Eikelboom, G.J. Hankey, J. Thom et al. // J. Thromb. Haemost. – 2005. – Vol. 3
(12). – Р. 2649-2655.
181. Eikelboom J.W. More on: enhanced antiplatelet effect of clopidogrel in
patients whose platelets are least inhibited by aspirin: a randomized crossover trial
/ J.W. Eikelboom, G.J. Hankey, J. Thom // J. Thromb. Haemost. – 2006. – Vol. 4
(7). – Р. 1639-1640.
182. Etminan M. Quantifying the Interaction between Angiotensin-Converting
Enzyme Inhibitors and Aspirin: Are We Using the Right Method? / M. Etminan, B.
Takkouche // Arch Intern Med. – 2001. – Vol. 161 (16). – Р. 2048-2049.
183. EUROASPIRE II Study Group Lifestyle and risk factor management and
use of drug therapies in coronary patients from 15 countries // Eur. Heart J. – 2001.
– № 22. – Р. 554-572.
184. European guidelines in cardiovascular diseases prevention in clinical
practice. Third Joint Task Force of European and other Societies on Cardiovascular
Diseases Prevention in Clinical practice / Eur. Heart J. – 2003. – № 24. – Р. 1601-
1610.
185. Faraci F.M. Vascular Protection. Superoxide Dismutase Isoforms in the
Vessel Wall / F.M. Faraci, S.P. Didion // Arteriosclerosis, Thrombosis, and
Vascular Biology. – 2004. – Vol. 24. – Р. 1367.
186. Faxon D.P. Antiplatelet therapy in populations at high risk of
atherothrombosis / D.P. Faxon, R.W. Nesto // J. Natl. Med. Assoc. – 2006. – Vol.
98 (5). – Р. 711-721.